John Porter is a member of the Molecula Board of Directors. With over 20 years of experience in the Life Science and Investment Banking industries, Mr. Porter provides valuable insights into the Company’s corporate development activities.
John is Managing Partner of Skylark Partners. Most recently John served as the CFO of AffiniPay a full-service merchant account provider specializing in retail and internet merchant accounts as well as processing for professional associations such as accountants, psychologists, and especially law professionals through its specialized platform LawPay.
Prior to Affinipay, he served as Chief Financial Officer for Astrotech Corporation (Nasdaq: ASTC) from 2007 to 2012. Previous to that John co-founded Arabella Securities, an investment banking firm that specialized in providing trading services and equity research on small-cap companies to institutional investors. He headed the Equity Research department, and published research on small companies in the Healthcare Technology sector. Arabella Securities subsequently merged with another broker/dealer in 2006 where John continued to lead the firm’s Healthcare investment banking practice.
From 1999 to 2004 John served as Director of Business Development for Luminex Corporation (Nasdaq: LMNX), a leading developer of biological testing technologies for the Diagnostic and life sciences industries. While at Luminex, John was responsible for the development, negotiation and management of Luminex’s strategic partnership program. During his tenure at Luminex, over 40 new strategic licensing partnerships were formed with companies around the globe including Hitachi Software (Japan), Qiagen (Germany), Tepnel (UK), Invitrogen (formerly Biosource, US), Inverness Medical (US), Millipore Corporation (formerly Upstate Biotech, US), and many other world class companies. John performed additional duties including strategic planning, product development, marketing management, and investor relations. John also served in multiple capacities during the preparation, and execution of Luminex’s initial public offering (IPO) in March 2000, where the company successfully raised approximately $100M.
John began his career as a senior associate in the global equity research division for Citigroup (formerly Salomon Smith Barney) in New York. At Citigroup, He was responsible for the day-to-day equity research of multiple corporations in the US. His research group consistently received awards, and high marks for quality and thorough analysis from multiple trade publications and clients such as Institutional Investor (First Team 1998 & 1999) and the Wall Street Journal (Best on the Street Analysts Survey). During his graduate studies, John was also an analyst in the equity research division of BankOne (formerly Hibernia Southcoast Capital) based in New Orleans.
John has a Bachelor of Science in Chemistry from Hampden-Sydney College in Virginia. In addition, John earned a Master of Business Administration from the A.B. Freeman School of Business at Tulane University and holds a Master of Science in Physical Chemistry & Material Sciences from Tulane University in New Orleans. John has co-authored several peer-review journal articles related to his specific areas of research. He has also passed the examinations for the Series 7, 24, 66, 86 and 87 designations by the Financial Industry Regulatory Authority (FINRA).
Connect with him on LinkedIn.